FDA Clears Device with BU-Developed Technology That Makes Skin Cancer Detection Easier
A new noninvasive skin cancer detection device—powered by technology pioneered by Irving J. Bigio, a professor at Boston University’s College of Engineering—aims to make telling the difference between a benign or potentially harmful mark easier and faster. The US Food & Drug Administration recently cleared for US markets DermaSensor, which uses light and artificial intelligence to examine skin lesions and assess whether a patient should be referred to a specialist. “It’s a positive statement about BU’s commitment to interdisciplinary research that involves the engineering and physical sciences, as well as the medical school,” says Bigio, who also holds positions in BU’s Chobanian & Avedisian School of Medicine and College of Arts & Sciences physics department. “They are supportive of collaborative research across schools.”
